Amylyx Pharmaceuticals Inc – Quartalsbilanz (NASDAQ:AMLX) | MetaTrader

Vollständige Grafik anzeigen

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.

Nachrichten

H.C. Wainwright bestätigt Kaufempfehlung für Amylyx nach Studienfortschritt

H.C. Wainwright hebt Kursziel für Amylyx-Aktie wegen Studienzuversicht auf 34 US-Dollar an

H.C. Wainwright raises Amylyx stock price target to $34 on trial confidence

Amylyx-Aktie gibt trotz übertroffener Erwartungen nach – Unsicherheit bei Studie belastet

Amylyx shares fall over 3% on trial uncertainty despite earnings beat

Stifel stuft Amylyx mit „Buy“ ein: Hohes Potenzial für Medikamentenkandidat

Stifel initiates Amylyx stock with buy rating on drug potential

Amylyx vor Quartalszahlen: Fokus auf Avexitide-Studie und Cash-Bestand

Amylyx set to report earnings as avexitide trial nears finish

H.C. Wainwright hebt Kursziel für Amylyx deutlich auf 28 Dollar an

Amylyx stock price target raised to $28 from $20 at H.C. Wainwright

Amylyx Pharmaceuticals: Back From The Dead (NASDAQ:AMLX)